Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedApr 16, 2026
DataAggregated Company Financials
Companies62
- 7D3.7%
- 3M6.8%
- 1Y88.0%
- YTD19.0%
The Biotech industry is up 3.7% in the last week, with Akeso up 7.2%. Meanwhile, Shanghai Bao Pharmaceuticals actually underperformed within the industry, shrinking 16% in the last week. This means that the industry has gained 88% over the past year. Earnings are forecast to grow by 31% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 16 Apr 2026 | HK$1.1t | HK$93.1b | -HK$3,929,929,554.24 | 27.3x | -291.9x | 12.3x |
| Sat, 14 Mar 2026 | HK$940.4b | HK$72.5b | -HK$12,064,322,882.28 | 50.1x | -77.9x | 13x |
| Mon, 09 Feb 2026 | HK$945.8b | HK$70.5b | -HK$14,017,336,394.37 | 34.9x | -67.5x | 13.4x |
| Wed, 07 Jan 2026 | HK$971.5b | HK$70.1b | -HK$13,848,383,625.59 | 37x | -70.2x | 13.9x |
| Fri, 05 Dec 2025 | HK$1.0t | HK$69.3b | -HK$12,923,474,795.84 | 40.9x | -79.3x | 14.8x |
| Sun, 02 Nov 2025 | HK$1.0t | HK$68.7b | -HK$12,796,738,967.86 | 43.9x | -79.1x | 14.7x |
| Tue, 30 Sep 2025 | HK$1.1t | HK$68.4b | -HK$13,103,625,671.21 | 50x | -83.7x | 16x |
| Thu, 28 Aug 2025 | HK$1.0t | HK$64.0b | -HK$13,490,046,964.50 | 51.4x | -77.1x | 16.2x |
| Sat, 26 Jul 2025 | HK$920.1b | HK$63.8b | -HK$12,529,430,293.15 | 37.7x | -73.4x | 14.4x |
| Mon, 23 Jun 2025 | HK$706.3b | HK$62.2b | -HK$12,096,481,816.17 | 32.5x | -58.4x | 11.3x |
| Wed, 21 May 2025 | HK$599.5b | HK$61.6b | -HK$11,844,777,793.93 | 30.8x | -50.6x | 9.7x |
| Fri, 18 Apr 2025 | HK$526.0b | HK$60.3b | -HK$12,128,865,816.48 | 28.6x | -43.4x | 8.7x |
| Sun, 16 Mar 2025 | HK$458.4b | HK$52.6b | -HK$16,861,129,116.45 | 22.6x | -27.2x | 8.7x |
| Tue, 11 Feb 2025 | HK$382.8b | HK$51.9b | -HK$17,255,560,722.66 | 14.2x | -22.2x | 7.4x |
| Thu, 09 Jan 2025 | HK$351.7b | HK$51.7b | -HK$17,168,577,251.79 | 11.4x | -20.5x | 6.8x |
| Sat, 07 Dec 2024 | HK$399.6b | HK$52.1b | -HK$17,335,520,655.52 | 11.1x | -23x | 7.7x |
| Mon, 04 Nov 2024 | HK$390.7b | HK$52.9b | -HK$17,788,453,167.47 | 11.3x | -22x | 7.4x |
| Wed, 02 Oct 2024 | HK$411.7b | HK$53.0b | -HK$18,162,881,010.09 | 12.4x | -22.7x | 7.8x |
| Fri, 30 Aug 2024 | HK$338.8b | HK$52.5b | -HK$21,986,804,947.03 | 11.5x | -15.4x | 6.5x |
| Sun, 28 Jul 2024 | HK$313.9b | HK$49.7b | -HK$19,485,991,582.66 | 11.7x | -16.1x | 6.3x |
| Tue, 25 Jun 2024 | HK$331.7b | HK$49.7b | -HK$19,461,001,638.58 | 11.7x | -17x | 6.7x |
| Thu, 23 May 2024 | HK$363.6b | HK$49.8b | -HK$19,364,801,216.55 | 12.3x | -18.8x | 7.3x |
| Sat, 20 Apr 2024 | HK$322.4b | HK$49.6b | -HK$19,911,350,266.52 | 10.8x | -16.2x | 6.5x |
| Mon, 18 Mar 2024 | HK$366.5b | HK$47.5b | -HK$20,433,312,530.06 | 17.6x | -17.9x | 7.7x |
| Wed, 14 Feb 2024 | HK$321.2b | HK$46.8b | -HK$20,174,942,054.91 | 15.6x | -15.9x | 6.9x |
| Fri, 12 Jan 2024 | HK$385.8b | HK$46.9b | -HK$20,262,766,347.00 | 17.7x | -19x | 8.2x |
| Sun, 10 Dec 2023 | HK$399.7b | HK$46.9b | -HK$20,222,468,345.00 | 17.7x | -19.8x | 8.5x |
| Tue, 07 Nov 2023 | HK$430.1b | HK$45.3b | -HK$19,010,469,517.00 | 13.6x | -22.6x | 9.5x |
| Thu, 05 Oct 2023 | HK$400.6b | HK$45.0b | -HK$19,133,521,889.00 | 13.7x | -20.9x | 8.9x |
| Sat, 02 Sep 2023 | HK$410.0b | HK$45.2b | -HK$16,778,616,585.00 | 15x | -24.4x | 9.1x |
| Mon, 31 Jul 2023 | HK$427.9b | HK$35.5b | -HK$23,380,251,031.00 | 28x | -18.3x | 12x |
| Wed, 28 Jun 2023 | HK$393.2b | HK$35.4b | -HK$23,290,725,942.00 | 24.5x | -16.9x | 11.1x |
| Fri, 26 May 2023 | HK$426.2b | HK$36.1b | -HK$23,813,255,373.00 | 29.5x | -17.9x | 11.8x |
| Sun, 23 Apr 2023 | HK$441.1b | HK$36.9b | -HK$24,127,461,338.00 | 18.5x | -18.3x | 11.9x |
Price to Earnings Ratio
-18.3x
Current Industry PE
- Investors are optimistic on the Hong Kong Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 10.1x is lower than the industry's current PS ratio of 12.3x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 36% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 0.33% | |
| Healthcare | 2.33% | |
| Biotech | 3.66% | |
| Biotech | 3.66% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 9926 Akeso | HK$149.00 | 10.0% +HK$12.4b | 79.6% | PS39.1x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$522.00 | 7.6% +HK$8.6b | 82.9% | PS51.5x | |
| 1801 Innovent Biologics | HK$92.40 | 5.3% +HK$8.1b | 95.6% | PE171.6x | |
| 9995 RemeGen | HK$118.00 | 9.6% +HK$5.8b | 254.4% | PE81.1x | |
| 1530 3SBio | HK$24.92 | 9.3% +HK$5.3b | 108.4% | PE6.4x |